TrialThe Lancet. Oncology2022

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.

Hedy L Kindler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.